Gut Liver.
2021 May;15(3):440-450. 10.5009/gnl19393.
Real-Life Effectiveness and Safety of Glecaprevir/Pibrentasvir for Korean Patients with Chronic Hepatitis C at a Single Institution
- Park YJ
1,2 - Woo HY1,2
- Heo J1,2
- Park SG3
- Hong YM1,4
- Yoon KT1,4
- Kim DU1,2
- Kim GH1,2
- Kim HH2,5
- Song GA1,2
- Cho M1,4
- Affiliations
-
- 1Department of Internal Medicine, College of Medicine, Pusan National University, Busan, Korea.
- 2Biomedical Research Institute, Pusan National University Hospital, Busan, Korea.
- 3Department of Internal Medicine, Good Samsun Hospital, Busan, Korea.
- 4Liver Center, Pusan National University Yangsan Hospital, Yangsan, Korea.
- 5Department of Laboratory Medicine, College of Medicine, Pusan National University, Busan, Korea.
- KMID: 2515848
- DOI: http://doi.org/10.5009/gnl19393
Abstract
- Background/Aims
Glecaprevir/pibrentasvir (G/P) is a combination of direct-acting antiviral agents that is an approved treatment for chronic infections by all six hepatitis C virus (HCV) genotypes. However, there are limited data on the effect of G/P in Korean patients in actual real-world settings. We evaluated the real-life effectiveness and safety of G/P at a single institution in Korea.
Methods
This retrospective, observational, cohort study used sustained virologic response at 12 weeks after treatment completion (SVR12) as the primary effectiveness endpoint. Safety and tolerability were also determined.
Results
We examined 267 individuals who received G/P for chronic HCV infections. There were 148 females (55.4%), and the overall median age was 63.0 years (range, 25 to 87 years). Eightythree patients (31.1%) had HCV genotype-1 and 182 (68.2%) had HCV-2. A total of 212 patients (79.4%) were HCV treatment-naïve, 200 (74.9%) received the 8-week treatment, 13 (4.9%) had received prior treatment for hepatocellular carcinoma, 37 (13.7%) had chronic kidney disease stage 3 or higher, and 10 (3.7%) were receiving dialysis. Intention to treat (ITT) analysis indicated that 256 (95.9%) achieved SVR12. A modified ITT analysis indicated that SVR12 was 97.7% (256/262). Six patients failed therapy because of posttreatment relapse. SVR12 was significantly lower in those who received prior sofosbuvir treatment (p=0.002) and those with detectable HCV RNA at week 4 (p=0.027). Seventy patients (26.2%) experienced one or more adverse events, and most of them were mild.
Conclusions
These real-life data indicated that G/P treatment was highly effective and well tolerated, regardless of viral genotype or patient comorbidities.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Comparison of Glecaprevir/Pibrentasvir and Sofosbuvir/Ledipasvir in Patients with Hepatitis C Virus Genotype 1 and 2 in South Korea
- Management of hepatitis C viral infection in chronic kidney disease patients on hemodialysis in the era of direct-acting antivirals
- Efficacy and Safety of Glecaprevir/Pibrentasvir in Korean Patients with Chronic Hepatitis C: A Pooled Analysis of Five Phase II/III Trials
- Safety and effectiveness of direct-acting antivirals in patients with chronic hepatitis C and chronic kidney disease
- Use of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus infection and severe renal impairment
